As of 1:22pm ET
| +0.08 / +1.41%|
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company. It is focused on the acquisition, development and commercialization of branded prescription products. The company's primary target markets include hospital acute care and gastroenterology. Its product portfolio includes Acetadote injection for the treatment of acetaminophen poisoning; Caldolor injection for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren injection, a phase II candidate for the treatment of critically ill hospitalized patients suffering from liver and kidney failure associated with hepatorenal syndrome; and Boxaban oral capsules, a phase II candidate for the treatment of patients with aspirin-exacerbated respiratory disease. Cumberland Pharmaceuticals was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
|A. J. Kazimi||Chairman & Chief Executive Officer|
|Leo Pavliv||Chief Development Officer & Senior VP-Operations|
|Rick Scott Greene||Chief Financial Officer, VP-Finance & Accounting|
|Amy Dix Rock||Senior Director-Regulatory & Scientific Affairs|
|James L. Herman||Compliance Officer & Vice President|